Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Эффективность и безопасность разных лекарственных форм ацетилсалициловой кислоты
________________________________________________
Vorobyeva N.M. Efficacy and safety of various acetylsalicylic acid formulations. Consilium Medicum. 2016; 18 (5): 82–88. DOI: 10.26442/2075-1753_2016.5.82-88
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: ацетилсалициловая кислота, лекарственная форма, эффективность, безопасность.
________________________________________________
Key words: acetylsalicylic acid, formulation, efficiency, safety.
2. Patrono C, Coller B, FitzGerald GA et al. Platelet-Active Drugs: The Relationships among dose, effectiveness, and side effects. The Seventh ACCP Conference of Antithrombotic and Thrombolytic Therapy 2004. Chest 2004; 126: 234s–264s.
3. Eikelboom JW, Hirsh J, Spencer FA et al. Antiplatelet Drugs. Antithrombotic therapy and prevention of thrombosis, 9th ACCP Evidence – based Clinical Practice Guidelines. Chest 2012; 141 (2): 89s–119s.
4. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.
5. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261–6.
6. Taylor DW, Barnett HJM, Haynes RB et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: randomised controlled trial. Lancet 1999; 353: 2179–83.
7. Mangano DT. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002; 347: 1309–17.
8. Pearson TA, Blair SN, Daniels SR et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patient without Coronary or other Atherosclerotic Vascular Diseases. Circulation 2002; 106: 388–91.
9. Насонов Е.Л., Каратеев А.Е. Поражения желудка, связанные с приемом нестероидных противовоспалительных препаратов. Клин. медицина. 2000; 78 (3): 4–10. / Nasonov E.L., Karateev A.E. Porazheniia zheludka, sviazannye s priemom nesteroidnykh protivovospalitel'nykh preparatov. Klin. meditsina. 2000; 78 (3): 4–10. [in Russian]
10. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs – differences and similarities. N Engl J Med 1991; 324 (24): 1716–25.
11. Wallace JL, McKnight GW. The mucoid cap over superficial gastric damage in the rat. A high-pH microenvironment dissipated by nonsteroidal antiinflammatory drugs and endothelin. Gastroenterology 1990; 99 (2): 295–304.
12. Somasundaram S, Hayllar H, Rafi S et al. The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: a review and hypothesis. Scand J Gastroenterol 1995; 30 (4): 289–99.
13. Sagar KA, Smyth MR. A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography. J Pharm Biomed Anal 1999; 21: 383–92.
14. Cox D, Maree AO, Dooley M et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006; 37: 2153–8.
15. Pedersen A, FitzGerald G. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311: 1206–11.
16. Endo H, Hosono K, Inamori M et al. Incidence of small bowel injury induced by low-dose aspirin: a crossover study using capsule endoscopy in healthy volunteers. Digestion 2009; 79: 44–51.
17. Endo H, Sakaib E, Higurashib T. Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy. Dig Liver Dis 2012; 44: 833–8.
18. Hirata Y, Kataoka H, Shimura T et al. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin. Scand J Gastroenterol 2011; 46: 803–9.
19. Баркаган З.С., Котовщикова Е.Ф. Сравнительный анализ основных и побочных эффектов различных форм ацетилсалициловой кислоты. Клин. фармакология и терапия. 2004; 13 (3): 1–4. / Barkagan Z.S., Kotovshchikova E.F. Sravnitel'nyi analiz osnovnykh i pobochnykh effektov razlichnykh form atsetilsalitsilovoi kisloty. Klin. farmakologiia i terapiia. 2004; 13 (3): 1–4. [in Russian]
20. Верткин А.Л., Аристархова О.Ю., Адонина Е.В. и др. Безопасность и фармакоэкономическая эффективность применения различных препаратов ацетилсалициловой кислоты у пациентов с ИБС. Рус. мед. журн. 2009; 17 (9): 570–5. / Vertkin A.L., Aristarkhova O.Iu., Adonina E.V. i dr. Bezopasnost' i farmakoekonomicheskaia effektivnost' primeneniia razlichnykh preparatov atsetilsalitsilovoi kisloty u patsientov s IBS. Rus. med. zhurn. 2009; 17 (9): 570–5. [in Russian]
21. Яковенко Э.П., Краснолобова Л.П., Яковенко А.В. и др. Влияние препаратов ацетилсалициловой кислоты на морфофункциональное состояние слизистой оболочки желудка у кардиологических пациентов пожилого возраста. Сердце. 2013; 12 (3): 145–50. / Iakovenko E.P., Krasnolobova L.P., Iakovenko A.V. i dr. Vliianie preparatov atsetilsalitsilovoi kisloty na morfofunktsional'noe sostoianie slizistoi obolochki zheludka u kardiologicheskikh patsientov pozhilogo vozrasta. Serdtse. 2013; 12 (3): 145–50. [in Russian]
22. Ломакин Н.В., Русанова А.В., Бурячковская Л.И., Вершинина М.Г. Сравнение антиагрегантной эффективности разных форм ацетилсалициловой кислоты. Сердце. 2014; 78 (4): 206–14. / Lomakin N.V., Rusanova A.V., Buriachkovskaia L.I., Vershinina M.G. Sravnenie antiagregantnoi effektivnosti raznykh form atsetilsalitsilovoi kisloty. Serdtse. 2014; 78 (4): 206–14. [in Russian]
23. Takada M, Fujimoto M, Hosomi K. Difference in risk of gastrointestinal complications between users of enteric-coated and buffered low-dose aspirin. Int J Clin Pharmacol Ther 2014; 52 (3): 181–91.
________________________________________________
1. Panchenko E.P., Dobrovol'skii A.. Trombozy v kardiologii. Mekhanizmy razvitiia i vozmozhnosti terapii. M.: Sport i kul'tura, 1999. [in Russian]
2. Patrono C, Coller B, FitzGerald GA et al. Platelet-Active Drugs: The Relationships among dose, effectiveness, and side effects. The Seventh ACCP Conference of Antithrombotic and Thrombolytic Therapy 2004. Chest 2004; 126: 234s–264s.
3. Eikelboom JW, Hirsh J, Spencer FA et al. Antiplatelet Drugs. Antithrombotic therapy and prevention of thrombosis, 9th ACCP Evidence – based Clinical Practice Guidelines. Chest 2012; 141 (2): 89s–119s.
4. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.
5. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261–6.
6. Taylor DW, Barnett HJM, Haynes RB et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: randomised controlled trial. Lancet 1999; 353: 2179–83.
7. Mangano DT. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002; 347: 1309–17.
8. Pearson TA, Blair SN, Daniels SR et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patient without Coronary or other Atherosclerotic Vascular Diseases. Circulation 2002; 106: 388–91.
9. Nasonov E.L., Karateev A.E. Porazheniia zheludka, sviazannye s priemom nesteroidnykh protivovospalitel'nykh preparatov. Klin. meditsina. 2000; 78 (3): 4–10. [in Russian]
10. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs – differences and similarities. N Engl J Med 1991; 324 (24): 1716–25.
11. Wallace JL, McKnight GW. The mucoid cap over superficial gastric damage in the rat. A high-pH microenvironment dissipated by nonsteroidal antiinflammatory drugs and endothelin. Gastroenterology 1990; 99 (2): 295–304.
12. Somasundaram S, Hayllar H, Rafi S et al. The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: a review and hypothesis. Scand J Gastroenterol 1995; 30 (4): 289–99.
13. Sagar KA, Smyth MR. A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography. J Pharm Biomed Anal 1999; 21: 383–92.
14. Cox D, Maree AO, Dooley M et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006; 37: 2153–8.
15. Pedersen A, FitzGerald G. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311: 1206–11.
16. Endo H, Hosono K, Inamori M et al. Incidence of small bowel injury induced by low-dose aspirin: a crossover study using capsule endoscopy in healthy volunteers. Digestion 2009; 79: 44–51.
17. Endo H, Sakaib E, Higurashib T. Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy. Dig Liver Dis 2012; 44: 833–8.
18. Hirata Y, Kataoka H, Shimura T et al. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin. Scand J Gastroenterol 2011; 46: 803–9.
19. Barkagan Z.S., Kotovshchikova E.F. Sravnitel'nyi analiz osnovnykh i pobochnykh effektov razlichnykh form atsetilsalitsilovoi kisloty. Klin. farmakologiia i terapiia. 2004; 13 (3): 1–4. [in Russian]
20. Vertkin A.L., Aristarkhova O.Iu., Adonina E.V. i dr. Bezopasnost' i farmakoekonomicheskaia effektivnost' primeneniia razlichnykh preparatov atsetilsalitsilovoi kisloty u patsientov s IBS. Rus. med. zhurn. 2009; 17 (9): 570–5. [in Russian]
21. Iakovenko E.P., Krasnolobova L.P., Iakovenko A.V. i dr. Vliianie preparatov atsetilsalitsilovoi kisloty na morfofunktsional'noe sostoianie slizistoi obolochki zheludka u kardiologicheskikh patsientov pozhilogo vozrasta. Serdtse. 2013; 12 (3): 145–50. [in Russian]
22. Lomakin N.V., Rusanova A.V., Buriachkovskaia L.I., Vershinina M.G. Sravnenie antiagregantnoi effektivnosti raznykh form atsetilsalitsilovoi kisloty. Serdtse. 2014; 78 (4): 206–14. [in Russian]
23. Takada M, Fujimoto M, Hosomi K. Difference in risk of gastrointestinal complications between users of enteric-coated and buffered low-dose aspirin. Int J Clin Pharmacol Ther 2014; 52 (3): 181–91.
ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1
natalyavorobjeva@mail.ru
________________________________________________
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
natalyavorobjeva@mail.ru